Articles
Early-Stage Pharmaceutical Company Overcomes Development Hurdles with Expert Clinical and CMC Regulatory Support
Posted on December 8, 202312/8/23
EVERSANA’s Regulatory Consulting Saves Big for Virtual Manufacturer: Uncovers Non-Compliance, Excessive Costs, and Risks
Posted on December 8, 202312/8/23
Leveraging QMS and Regulatory Expertise to Support Tissue Compliance
Posted on October 20, 202310/20/23
Robust Signal Management to Achieve Patient Safety-Signal Case Study
Posted on October 3, 202310/3/23
Successful Implementation of End-To-End Pharmacovigilance Services For Drug-Device Combination Product Portfolio
Posted on October 3, 202310/3/23
FDA Inspection Win for Mid-Sized Pharma (50+ Products) with Extensive Generic Product Portfolio
Posted on October 3, 202310/3/23
FDA Inspection Win For a Mid-Sized Pharma Company with More Than 40+ Products in the USA and Outside the USA
Posted on October 3, 202310/3/23
Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)
- Journal/Conference:
- ASH 2020
- Author(s):
- Chen, C., Disher, T., Siddiqui, M., La Torre, I., Skikne, B., Suero, B., Cameron, H., Gavanji, R., Cameron, C.
- Publication Date:
- 2020
- Topic/Therapeutic Area:
- Oncology
- Condition:
- Acute Myeloid Leukemia